Internal Medicine, Rheumatology · Jacksonville, FL
NPI
1144424722
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
9765 San Jose Blvd Ste 103
Jacksonville, FL, 32257
Phone (904) 517-8222
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.2M
269,266 services
Medicare patients, 2024
924
Average age 73
Drug cost, 2024
$5.2M
4,222 prescriptions
Company payments, 2025
$16K
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Swati M Shah was code J3262 (injection, tocilizumab, 1 mg), 142,394 times for 46 patients. In total Swati M Shah billed 269,266 services in 48 codes, and Medicare paid $3.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-09-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 142,394 | 46 | $4.74 | $675K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 45,513 | 90 | $9.28 | $422K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 24,050 | 58 | $32.87 | $791K |
| J9312 Injection, rituximab, 10 mg | Office | 7,600 | 44 | $60.73 | $462K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 5,811 | 38 | $24.14 | $140K |
| J0897 Injection, denosumab, 1 mg | Office | 5,280 | 71 | $20.29 | $107K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,249 | 45 | $0.20 | $250 |
| 99214 Office E&M - Established | Office | 1,137 | 644 | $86.77 | $99K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 764 | 20 | $0.10 | $75.28 |
| 36415 Venipuncture Blood Collection | Office | 665 | 280 | $8.51 | $5,659 |
| 96413 Chemotherapy Administration | Office | 585 | 172 | $93.65 | $55K |
| 96365 Intravenous Infusion, Hydration | Office | 557 | 171 | $45.57 | $25K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 556 | 381 | $12.71 | $7,069 |
| 96415 Chemotherapy Administration | Office | 389 | 89 | $19.23 | $7,479 |
| 96375 Injection Administration | Office | 202 | 58 | $10.46 | $2,113 |
By year: 2022 $793K for 52,204 services; 2023 $350K for 15,646 services; 2024 $3.2M for 269,266 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 665 | 280 | $8.51 | $5,659 |
Medicare prescription drug claims, 2024
In 2024, the drug Swati M Shah prescribed most often to Medicare patients was Prednisone, with 580 prescriptions and refills. In total Swati M Shah wrote 4,222 Medicare prescriptions that cost $5.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 580 | 1,141 | 272 | $5,481 |
| Methotrexate Methotrexate Sodium | 360 | 939 | 146 | $9,452 |
| Hydroxychloroquine Sulfate Generic | 296 | 851 | 136 | $13K |
| Gabapentin Generic | 189 | 479 | 80 | $4,122 |
| Folic Acid Generic | 145 | 355 | 52 | $1,149 |
| Pregabalin Generic | 143 | 341 | 56 | $6,821 |
| Sodium Chloride 0.9 % Sodium Chloride | 122 | 149 | 31 | $395 |
| Tramadol Hcl Generic | 113 | 113 | 41 | $857 |
| Simponi Aria Golimumab | 112 | 132 | 26 | $795K |
| Tizanidine Hcl Generic | 111 | 206 | 55 | $1,936 |
| Duloxetine Hcl Generic | 108 | 261 | 36 | $2,229 |
| Methylprednisolone Generic | 98 | 118 | 57 | $913 |
| Humira(Cf) Pen Adalimumab | 96 | 97 | 13 | $774K |
| Sulfasalazine Generic | 95 | 255 | 46 | $1,727 |
| Allopurinol Generic | 80 | 222 | 35 | $807 |
Brand drugs: - claims; generic drugs: 3,299 claims; opioid claims: 165.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Swati M Shah $16K ($16K in general payments such as food, travel and fees) from 30 companies. The largest payer was GlaxoSmithKline, LLC. with $11K.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 20 | $11K |
| Janssen Biotech, Inc. JNJ | 11 | $1,212 |
| Abbvie Inc. ABBV | 35 | $677 |
| Amgen Inc. AMGN | 36 | $634 |
| Novartis Pharmaceuticals Corporation NVS | 22 | $451 |
| UCB, Inc. UCB.BR | 26 | $447 |
| AstraZeneca Pharmaceuticals LP AZN | 14 | $398 |
| Pfizer Inc. PFE | 17 | $324 |
| Mallinckrodt Hospital Products Inc. | 10 | $179 |
| Lilly USA, LLC LLY | 8 | $161 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.